Stock 460 SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Sihuan Pharmaceutical Holdings Group Ltd. Share Price Shanghai - Hong Kong Stock Connect

Equities

460

BMG8162K1137

Pharmaceuticals

Financials

Sales 2024 * 2.73B 378M 2.95B 31.47B Sales 2025 * 3.19B 440M 3.44B 36.68B Capitalization 5.25B 725M 5.66B 60.39B
Net income 2024 * 107M 14.78M 115M 1.23B Net income 2025 * 337M 46.55M 364M 3.88B EV / Sales 2024 * 1.92 x
Net cash position 2024 * - 0 0 0 Net cash position 2025 * - 0 0 0 EV / Sales 2025 * 1.65 x
P/E ratio 2024 *
56.5 x
P/E ratio 2025 *
14.1 x
Employees -
Yield 2024 *
8.85%
Yield 2025 *
8.85%
Free-Float 44.97%
More Fundamentals * Assessed data

Chart Sihuan Pharmaceutical Holdings Group Ltd.

Dynamic Chart

Latest news about Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10% MT
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government MT
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments MT
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China MT
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring MT
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug MT
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets CI
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3% MT
China Grants Registration Approval to Sihuan Pharmaceutical's Insulin Products MT
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes CI
China's Medical Products Administrator Approves Sihuan Pharma Unit's Diabetes Drug MT
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical CI
China Accepts New Drug Application of Sihuan Pharmaceutical Subsidiary's Breast Cancer Treatment MT
China Accepts New Drug Application for Sihuan Pharmaceutical Unit's Breast Cancer Tablets MT
More news

Analyst Recommendations on Sihuan Pharmaceutical Holdings Group Ltd.

THE BLACKSTONE GROUP L.P. : Blackstone hires Morgan Stanley executive for China: sources RE
More recommendations

Press releases Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023 AQ
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA AQ
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, progresses at full speed in innovative research and development Presents major research results of birociclib, the start product, at the international stage in ASCO AQ
Sihuan Pharmaceutical(0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate 'Positive Energy' of China's Medical Aesthetics Industry AQ
Sihuan Pharmaceutical : VOLUNTARY ANNOUNCEMENT - INSULIN ASPART 30 INJECTION DEVELOPED BY SIHUAN PHARMACEUTICAL ACHIEVED EQUIVALENT CLINICAL RESULTS IN EFFICACY AND SAFETY STUDY AS ORIGINATOR DRUG PU
More press releases

Managers and Directors - Sihuan Pharmaceutical Holdings Group Ltd.

Managers TitleAgeSince
Wei Cheng Guo FOU
 Founder 60 01/01/01
Gui Li Miao DFI
 Director of Finance/CFO 50 -
Zhong Xin Jia COO
 Chief Operating Officer 65 01/07/01
Members of the board TitleAgeSince
Feng Sheng Che FOU
 Founder 63 01/01/01
Wei Cheng Guo FOU
 Founder 60 01/01/01
Jiong Long Zhang CIO
 Chief Investment Officer 62 18/06/18
More insiders

Company Profile

Sihuan Pharmaceutical Holdings Group Ltd is a holding company mainly engaged in pharmaceutical manufacturing business. The Company operates three segments. Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetics comprehensive solutions. Innovative Medicine and Other Medicine segment is engaged in the research and development of innovative drugs in the fields of digestion, oncology, non-alcoholic hepatitis, diabetes and complications. The Company also operates Generic Medicine segment.
Sector
Pharmaceuticals
Calendar
27/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 460 Stock
  4. 460 Stock